Table 4.
Intracerebral Progression After Fibrinogen Concentrate Administration.
| Patient number | ICH classification pre fibrinogen concentrate | Intraventricular extension pre-fibrinogen concentrate | ICH classification post fibrinogen concentrate 24 hour head-CT | Intraventricular extension post fibrinogen concentrate | Baseline fibrinogen level (mg/dL) | Final fibrinogen level after fibrinogen concentrate treatment (mg/dL) |
|---|---|---|---|---|---|---|
| 1 | PH1 | No | PH1 | No | 116 | 307 |
| 2 | PH1/IVH | Yes | PH1/HI1 | Yes | 160 | 389 |
| 3 | PH1/IVH | Yes | PH1 | Yes | 465 | 457 |
| 4 | PH1/IVH | Yes | PH1multiple | Yes | 445 | 417 |
| 6 | PH1/SAH | No | PH1multiple | No | 288 | 320 |
| 7a | SAH | No | PH2/SAH | Yes | 93 | 236 |
| 8 | PH2/SAH/SDH | Yes | PH2/SAH/SDH | Yes | 258 | 241 |
| 9 | PH2/SAH | Yes | PH2/SAH | Yes | 221 | 322 |
| 10a | HI2 | No | P H2 | No | 291 | 363 |
| 11 | HI2 | No | HI2 | No | 60 | 415 |
| 12a | PH2 | No | PH2 | Yes | 254 | 305 |
| 13a | PH1 | No | PH1/SDH | Yes | Not available | 226 |
| 14 | PH1 | No | PH1 | No | 122 | 311 |
| 15 | PH2 | No | PH2/SAH | No | 359 | 432 |
| 16 | HI2 | No | HI2 | No | 276 | 248 |
| 18 | PH2/SAH | No | PH2/SAH | No | 321 | 325 |
| 19 | PH2/SAH/SDH | No | PH2/SAH/SDH | No | 397 | 393 |
| 20 | PH2/SAH | Yes | PH2/SAH | Yes | Not available | Not available |
| 21 | HI1 | Yes | HI1 | Yes | 356 | 397 |
| 22 | PH2/SAH | Yes | PH2/SAH | Yes | Not available | 309 |
| 23a | PH2/SDH | No | PH2/SDH | Yes | Not available | 354 |
| 24 | PH2/SAH | No | PH2/SAH | No | 166 | 267 |
aPatient 7, 10, 12, 13, 23 were considered to have clinically significant progression after fibrinogen concentrate administration.
Note: Patient 5 and 17 was excluded due to extracerebral hemorrhage origin.